Can-Fite BioPharma (NYSE:CANF) Cut to “Sell” at StockNews.com

StockNews.com cut shares of Can-Fite BioPharma (NYSE:CANF) from a hold rating to a sell rating in a report published on Friday.

Several other analysts have also recently issued reports on CANF. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Can-Fite BioPharma in a report on Thursday, December 5th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Can-Fite BioPharma in a research note on Tuesday, November 12th.

Can-Fite BioPharma Price Performance

Shares of Can-Fite BioPharma stock opened at $1.58 on Friday. The company has a market capitalization of $5.59 million, a PE ratio of -0.88 and a beta of 1.32. Can-Fite BioPharma has a 1-year low of $1.29 and a 1-year high of $4.69. The business has a 50-day moving average of $2.15 and a 200-day moving average of $2.47.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC boosted its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. 21.00% of the stock is currently owned by hedge funds and other institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.